Author: mineralystx

AHA Scientific Sessions 2023 Poster: Lorundrostat for Treatment of Obesity-Related, Aldosterone-Dependent Hypertension

– An Endotype-Specific, Targeted Approach to the Treatment of Uncontrolled Hypertension

ASN Kidney Week 2023 Poster: Identification of a Hypertensive Endotype with a Median Treatment Effect of -32 mmHg in Response to the Novel Aldosterone Synthase Inhibitor Lorundrostat

AHA Hypertension 2023 Presentation: Target-HTN Trial on the Safety and Efficacy of Lorundrostat (MLS-101) in Patients With Uncontrolled Hypertension

ACC 2023 Poster: First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor

ACC 2023 Poster: Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation